Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation
Alzheimer's disease (AD) is known as a complex multifactorial syndrome and both metal chelators and amyloid β peptide (Aβ) inhibitors show promise against AD. Herein, four small hybrid compounds have been designed and synthesized utilizing 8-hydroxyquinoline, pyridine or imidazole as chelators...
Gespeichert in:
| Veröffentlicht in: | Journal of inorganic biochemistry 2021-11, Vol.224, p.111591-111591, Article 111591 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 111591 |
|---|---|
| container_issue | |
| container_start_page | 111591 |
| container_title | Journal of inorganic biochemistry |
| container_volume | 224 |
| creator | Peng, Yan-Bo Tao, Can Tan, Cai-Ping Zhao, Ping |
| description | Alzheimer's disease (AD) is known as a complex multifactorial syndrome and both metal chelators and amyloid β peptide (Aβ) inhibitors show promise against AD. Herein, four small hybrid compounds have been designed and synthesized utilizing 8-hydroxyquinoline, pyridine or imidazole as chelators and benzimidazole as the recognition moiety for AD treatment. These conjugates can capture Cu2+ from Aβ and become dimers upon Cu2+ coordination and show high efficiency for both Cu2+ elimination and Aβ assembly inhibition. Besides, these designed complexes can inhibit the production of Aβ-induced reactive oxygen species (ROS), protect mitochondria from damage, and improve the survival rate of neuron cells. Our work provides a new strategy to combine hydrophobic interaction and metal ion chelation to design amyloid inhibitors.
[Display omitted]
•Four Ru(II) complexes are designed and synthesized to treat Alzheimer's disease (AD).•The Ru(II) complexes can capture Cu2+ from amyloid β peptide (Aβ).•The Ru(II) complexes can inhibit Aβ assembly.•The Ru(II) complexes can improve the survival rate of neuron cells. |
| doi_str_mv | 10.1016/j.jinorgbio.2021.111591 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2566039013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0162013421002385</els_id><sourcerecordid>2566039013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-27f61a484e91808ba57d268306f3e2fb8650a742e84a95d51ad8270e67e9ac373</originalsourceid><addsrcrecordid>eNqFkM9O3DAQh62KqmyBV2h9hEMW_42T4wq1dCUkLvRsOckk8SqJjZ0g8lp9kD5TDUu5chpp5vvNaD6EvlOypYTm14ftwU4udJV1W0YY3VJKZUk_oQ0tFM84F-IEbRLJMkK5OEVfYzwQQqQU6gs6TWNJBCUbBPupt5WdrZuwa_Hu7x_swc-2AWy6LkBnXkfVisMy9zDZZbzc76-wd8Pq12CbdcC1G_0AzxDx3Ae3dH3qeA8B1z0Mr_lz9Lk1Q4SLt3qGfv_88XDzK7u7v93f7O6ymis6Z0y1OTWiEFDSghSVkaphecFJ3nJgbVXkkhglGBTClLKR1DQFUwRyBaVJK_gZujzu9cE9LhBnPdpYwzCYCdwSNZN5TniZlCRUHdE6uBgDtNoHO5qwakr0i2N90O-O9YtjfXSckt_ejizVCM177r_UBOyOAKRXnywEHWsLUw2NDVDPunH2wyP_AE6Nku8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2566039013</pqid></control><display><type>article</type><title>Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Peng, Yan-Bo ; Tao, Can ; Tan, Cai-Ping ; Zhao, Ping</creator><creatorcontrib>Peng, Yan-Bo ; Tao, Can ; Tan, Cai-Ping ; Zhao, Ping</creatorcontrib><description>Alzheimer's disease (AD) is known as a complex multifactorial syndrome and both metal chelators and amyloid β peptide (Aβ) inhibitors show promise against AD. Herein, four small hybrid compounds have been designed and synthesized utilizing 8-hydroxyquinoline, pyridine or imidazole as chelators and benzimidazole as the recognition moiety for AD treatment. These conjugates can capture Cu2+ from Aβ and become dimers upon Cu2+ coordination and show high efficiency for both Cu2+ elimination and Aβ assembly inhibition. Besides, these designed complexes can inhibit the production of Aβ-induced reactive oxygen species (ROS), protect mitochondria from damage, and improve the survival rate of neuron cells. Our work provides a new strategy to combine hydrophobic interaction and metal ion chelation to design amyloid inhibitors.
[Display omitted]
•Four Ru(II) complexes are designed and synthesized to treat Alzheimer's disease (AD).•The Ru(II) complexes can capture Cu2+ from amyloid β peptide (Aβ).•The Ru(II) complexes can inhibit Aβ assembly.•The Ru(II) complexes can improve the survival rate of neuron cells.</description><identifier>ISSN: 0162-0134</identifier><identifier>EISSN: 1873-3344</identifier><identifier>DOI: 10.1016/j.jinorgbio.2021.111591</identifier><identifier>PMID: 34450410</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Alzheimer's disease ; Amyloid beta-Peptides - antagonists & inhibitors ; Amyloid beta-Peptides - metabolism ; Aβ peptides ; Benzimidazoles - pharmacology ; Cell Line, Tumor ; Cell Survival - drug effects ; Chelating Agents - chemistry ; Chelating Agents - pharmacology ; Coordination Complexes - chemistry ; Copper - chemistry ; Cu2+ chelating ; Humans ; Mitochondria - metabolism ; Neurons - metabolism ; Oxyquinoline - pharmacology ; Protein Aggregates ; Protein Aggregation, Pathological - metabolism ; Reactive Oxygen Species - metabolism ; Ruthenium - chemistry ; Ruthenium - pharmacology ; Ruthenium complexes</subject><ispartof>Journal of inorganic biochemistry, 2021-11, Vol.224, p.111591-111591, Article 111591</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-27f61a484e91808ba57d268306f3e2fb8650a742e84a95d51ad8270e67e9ac373</citedby><cites>FETCH-LOGICAL-c371t-27f61a484e91808ba57d268306f3e2fb8650a742e84a95d51ad8270e67e9ac373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jinorgbio.2021.111591$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34450410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Yan-Bo</creatorcontrib><creatorcontrib>Tao, Can</creatorcontrib><creatorcontrib>Tan, Cai-Ping</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><title>Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation</title><title>Journal of inorganic biochemistry</title><addtitle>J Inorg Biochem</addtitle><description>Alzheimer's disease (AD) is known as a complex multifactorial syndrome and both metal chelators and amyloid β peptide (Aβ) inhibitors show promise against AD. Herein, four small hybrid compounds have been designed and synthesized utilizing 8-hydroxyquinoline, pyridine or imidazole as chelators and benzimidazole as the recognition moiety for AD treatment. These conjugates can capture Cu2+ from Aβ and become dimers upon Cu2+ coordination and show high efficiency for both Cu2+ elimination and Aβ assembly inhibition. Besides, these designed complexes can inhibit the production of Aβ-induced reactive oxygen species (ROS), protect mitochondria from damage, and improve the survival rate of neuron cells. Our work provides a new strategy to combine hydrophobic interaction and metal ion chelation to design amyloid inhibitors.
[Display omitted]
•Four Ru(II) complexes are designed and synthesized to treat Alzheimer's disease (AD).•The Ru(II) complexes can capture Cu2+ from amyloid β peptide (Aβ).•The Ru(II) complexes can inhibit Aβ assembly.•The Ru(II) complexes can improve the survival rate of neuron cells.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer's disease</subject><subject>Amyloid beta-Peptides - antagonists & inhibitors</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Aβ peptides</subject><subject>Benzimidazoles - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Chelating Agents - chemistry</subject><subject>Chelating Agents - pharmacology</subject><subject>Coordination Complexes - chemistry</subject><subject>Copper - chemistry</subject><subject>Cu2+ chelating</subject><subject>Humans</subject><subject>Mitochondria - metabolism</subject><subject>Neurons - metabolism</subject><subject>Oxyquinoline - pharmacology</subject><subject>Protein Aggregates</subject><subject>Protein Aggregation, Pathological - metabolism</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Ruthenium - chemistry</subject><subject>Ruthenium - pharmacology</subject><subject>Ruthenium complexes</subject><issn>0162-0134</issn><issn>1873-3344</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9O3DAQh62KqmyBV2h9hEMW_42T4wq1dCUkLvRsOckk8SqJjZ0g8lp9kD5TDUu5chpp5vvNaD6EvlOypYTm14ftwU4udJV1W0YY3VJKZUk_oQ0tFM84F-IEbRLJMkK5OEVfYzwQQqQU6gs6TWNJBCUbBPupt5WdrZuwa_Hu7x_swc-2AWy6LkBnXkfVisMy9zDZZbzc76-wd8Pq12CbdcC1G_0AzxDx3Ae3dH3qeA8B1z0Mr_lz9Lk1Q4SLt3qGfv_88XDzK7u7v93f7O6ymis6Z0y1OTWiEFDSghSVkaphecFJ3nJgbVXkkhglGBTClLKR1DQFUwRyBaVJK_gZujzu9cE9LhBnPdpYwzCYCdwSNZN5TniZlCRUHdE6uBgDtNoHO5qwakr0i2N90O-O9YtjfXSckt_ejizVCM177r_UBOyOAKRXnywEHWsLUw2NDVDPunH2wyP_AE6Nku8</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Peng, Yan-Bo</creator><creator>Tao, Can</creator><creator>Tan, Cai-Ping</creator><creator>Zhao, Ping</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202111</creationdate><title>Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation</title><author>Peng, Yan-Bo ; Tao, Can ; Tan, Cai-Ping ; Zhao, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-27f61a484e91808ba57d268306f3e2fb8650a742e84a95d51ad8270e67e9ac373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer's disease</topic><topic>Amyloid beta-Peptides - antagonists & inhibitors</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Aβ peptides</topic><topic>Benzimidazoles - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Chelating Agents - chemistry</topic><topic>Chelating Agents - pharmacology</topic><topic>Coordination Complexes - chemistry</topic><topic>Copper - chemistry</topic><topic>Cu2+ chelating</topic><topic>Humans</topic><topic>Mitochondria - metabolism</topic><topic>Neurons - metabolism</topic><topic>Oxyquinoline - pharmacology</topic><topic>Protein Aggregates</topic><topic>Protein Aggregation, Pathological - metabolism</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Ruthenium - chemistry</topic><topic>Ruthenium - pharmacology</topic><topic>Ruthenium complexes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Yan-Bo</creatorcontrib><creatorcontrib>Tao, Can</creatorcontrib><creatorcontrib>Tan, Cai-Ping</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of inorganic biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Yan-Bo</au><au>Tao, Can</au><au>Tan, Cai-Ping</au><au>Zhao, Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation</atitle><jtitle>Journal of inorganic biochemistry</jtitle><addtitle>J Inorg Biochem</addtitle><date>2021-11</date><risdate>2021</risdate><volume>224</volume><spage>111591</spage><epage>111591</epage><pages>111591-111591</pages><artnum>111591</artnum><issn>0162-0134</issn><eissn>1873-3344</eissn><abstract>Alzheimer's disease (AD) is known as a complex multifactorial syndrome and both metal chelators and amyloid β peptide (Aβ) inhibitors show promise against AD. Herein, four small hybrid compounds have been designed and synthesized utilizing 8-hydroxyquinoline, pyridine or imidazole as chelators and benzimidazole as the recognition moiety for AD treatment. These conjugates can capture Cu2+ from Aβ and become dimers upon Cu2+ coordination and show high efficiency for both Cu2+ elimination and Aβ assembly inhibition. Besides, these designed complexes can inhibit the production of Aβ-induced reactive oxygen species (ROS), protect mitochondria from damage, and improve the survival rate of neuron cells. Our work provides a new strategy to combine hydrophobic interaction and metal ion chelation to design amyloid inhibitors.
[Display omitted]
•Four Ru(II) complexes are designed and synthesized to treat Alzheimer's disease (AD).•The Ru(II) complexes can capture Cu2+ from amyloid β peptide (Aβ).•The Ru(II) complexes can inhibit Aβ assembly.•The Ru(II) complexes can improve the survival rate of neuron cells.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34450410</pmid><doi>10.1016/j.jinorgbio.2021.111591</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0162-0134 |
| ispartof | Journal of inorganic biochemistry, 2021-11, Vol.224, p.111591-111591, Article 111591 |
| issn | 0162-0134 1873-3344 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2566039013 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimer's disease Amyloid beta-Peptides - antagonists & inhibitors Amyloid beta-Peptides - metabolism Aβ peptides Benzimidazoles - pharmacology Cell Line, Tumor Cell Survival - drug effects Chelating Agents - chemistry Chelating Agents - pharmacology Coordination Complexes - chemistry Copper - chemistry Cu2+ chelating Humans Mitochondria - metabolism Neurons - metabolism Oxyquinoline - pharmacology Protein Aggregates Protein Aggregation, Pathological - metabolism Reactive Oxygen Species - metabolism Ruthenium - chemistry Ruthenium - pharmacology Ruthenium complexes |
| title | Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T05%3A18%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20A%CE%B2%20peptide%20aggregation%20by%20ruthenium(II)%20polypyridyl%20complexes%20through%20copper%20chelation&rft.jtitle=Journal%20of%20inorganic%20biochemistry&rft.au=Peng,%20Yan-Bo&rft.date=2021-11&rft.volume=224&rft.spage=111591&rft.epage=111591&rft.pages=111591-111591&rft.artnum=111591&rft.issn=0162-0134&rft.eissn=1873-3344&rft_id=info:doi/10.1016/j.jinorgbio.2021.111591&rft_dat=%3Cproquest_cross%3E2566039013%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2566039013&rft_id=info:pmid/34450410&rft_els_id=S0162013421002385&rfr_iscdi=true |